



New Waived Tests

MLN Matters Number: MM12841

Related CR Release Date: August 4, 2022

Related Change Request (CR) Number: 12841

Effective Date: October 1, 2022

Related CR Transmittal Number: R11547CP

Implementation Date: October 3, 2022

Provider Types Affected

This MLN Matters Article is for providers billing Medicare Administrative Contractors (MACs) for Clinical Laboratory Improvement Amendments (CLIA) waived laboratory tests they provide to Medicare patients.

Provider Action Needed

Make sure your billing staff knows about these changes:

- CLIA requirements
- New CLIA waived tests approved by the FDA
- Use of modifier QW for CLIA-waived tests

Background

CLIA regulations require a facility to be appropriately certified for each test they do. CMS edits laboratory claims at the CLIA certificate level to make sure that Medicare and Medicaid only pay for laboratory tests in a facility with a valid, current CLIA certificate.

Since these tests are marketed immediately after approval, we tell the MACs of the new tests, so they process claims accurately. There are 8 newly added waived complexity tests. These new tests must have the modifier QW to be recognized as a waived test. The HCPCS code, effective date, and description for these latest tests are:

- 87651QW, November 09, 2020, Mesa Biotech Accula {Accula Strep A Test}
- G0475QW, February 07, 2022, Abbott Diagnostics Determine HIV-1/2 Ag/Ab Combo {Fingerstick whole blood}
- 80305QW, March 01, 2022, Noble Medical Inc. Noble Dip Card/Drug Test Cup
- 82465QW, March 25, 2022, PTS Panels Cholesterol Test Strips, Polymer Technology Systems Inc. CardioChek Plus Test System {PTS Panels Cholesterol Test Strips}
- 82010QW, 82962, April 07, 2022, Apex Biotechnology Corp. MTM301 Blood Glucose and Ketone Monitoring System



- 80305QW, May 09, 2022, T&D Diagnostics Canada Pvt. Ltd. Sienna Multi-Drug Test (Cup and Dip Card)
- 80305QW, June 01, 2022, NexScreen Gen2 Multi-Drug Urine Test Cup
- 80305QW, June 01, 2022, NexScreen Gen2 Multi-Drug Urine Test Dip Card

In <u>CR 10819</u>, the attachment to the transmittal was re-organized to include a generic test system name and a statement to refer to the FDA waived analyte Internet site for HCPCS codes with more than 10 test systems listed.

Starting with <u>CR 12841</u>, the attachment won't mention a specific test system for HCPCS codes with more than 5 test systems. The added codes in the attachment will now be mentioned in a generic manner. They are:

- 82010QW, 82962 for test systems monitoring blood glucose levels and measuring ketones in whole blood
- 80061QW, 82465QW, 83718QW, and 84478QW for test systems measuring total cholesterol, high-density lipoprotein (HDL) cholesterol, and triglycerides levels in whole blood
- 82465QW and 83718QW for test systems measuring total cholesterol and HDL cholesterol in whole blood
- 83001QW
- 83036QW
- 82044QW
- 83037QW
- 83986QW for body fluid pH level, vaginal
- 84443QW
- 87077QW
- 87502QW

The tests on the first page of the <u>list</u> attached to CR 12841 (HCPCS codes 81002, 81025, 82270, 82272, 82962, 83026, 84830, 85013, and 85651) don't require a QW modifier to be recognized as a waived test.

MACs won't search their files to either take back payment or retroactively pay claims affected by CR 12841. They should adjust such claims you bring to their attention.

More Information

We issued <u>CR 12841</u> to your MAC as the official instruction for this change.

For more information, find your MAC's website.



Document History

Date of Change		Description	
August 4, 2022	Initial article released.		

Disclaimer: Paid for by the Department of Health & Human Services. This article was prepared as a service to the public and is not intended to grant rights or impose obligations. This article may contain references or links to statutes, regulations, or other policy materials. The information provided is only intended to be a general summary. It is not intended to take the place of either the written law or regulations. We encourage readers to review the specific statutes, regulations and other interpretive materials for a full and accurate statement of their contents. CPT only copyright 2021 American Medical Association. All rights reserved.

Copyright © 2013-2022, the American Hospital Association, Chicago, Illinois. Reproduced by CMS with permission. No portion of the AHA copyrighted materials contained within this publication may be copied without the express written consent of the AHA. AHA copyrighted materials including the UB-04 codes and descriptions may not be removed, copied, or utilized within any software, product, service, solution or derivative work without the written consent of the AHA. If an entity wishes to utilize any AHA materials, please contact the AHA at 312-893-6816. Making copies or utilizing the content of the UB-04 Manual, including the codes and/or descriptions, for internal purposes, resale and/or to be used in any product or publication; creating any modified or derivative work of the UB-04 Manual and/or codes and descriptions; and/or making any commercial use of UB-04 Manual or any portion thereof, including the codes and/or descriptions, is only authorized with an express license from the American Hospital Association. To license the electronic data file of UB-04 Data Specifications, contact Tim Carlson at (312) 893-6816. You may also contact us at ub04@healthforum.com

The American Hospital Association (the "AHA") has not reviewed, and is not responsible for, the completeness or accuracy of any information contained in this material, nor was the AHA or any of its affiliates, involved in the preparation of this material, or the analysis of information provided in the material. The views and/or positions presented in the material do not necessarily represent the views of the AHA. CMS and its products and services are not endorsed by the AHA or any of its affiliates.

